Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 14 g/l; arginine, quantity: 12 g/l; glycine, quantity: 11 g/l; histidine, quantity: 3 g/l; isoleucine, quantity: 5 g/l; leucine, quantity: 7.4 g/l; lysine acetate, quantity: 9.31 g/l (equivalent: lysine, qty 6.6 g/l); methionine, quantity: 4.3 g/l; phenylalanine, quantity: 5.1 g/l; proline, quantity: 11.2 g/l; serine, quantity: 6.5 g/l; taurine, quantity: 1 g/l; threonine, quantity: 4.4 g/l; tryptophan, quantity: 2 g/l; tyrosine, quantity: 400 mg/l; valine, quantity: 6.2 g/l - injection, solution - excipient ingredients: glacial acetic acid; water for injections - to supply amino acids as part of a composite admixture of total parenteral nutrition.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 14 g/l; arginine, quantity: 12 g/l; glycine, quantity: 11 g/l; histidine, quantity: 3 g/l; isoleucine, quantity: 5 g/l; leucine, quantity: 7.4 g/l; lysine acetate, quantity: 9.31 g/l (equivalent: lysine, qty 6.6 g/l); methionine, quantity: 4.3 g/l; phenylalanine, quantity: 5.1 g/l; proline, quantity: 11.2 g/l; serine, quantity: 6.5 g/l; taurine, quantity: 1 g/l; threonine, quantity: 4.4 g/l; tryptophan, quantity: 2 g/l; tyrosine, quantity: 400 mg/l; valine, quantity: 6.2 g/l - injection, solution - excipient ingredients: glacial acetic acid; water for injections - to supply amino acids as part of a composite admixture of total parenteral nutrition.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 300 g/l - injection, intravenous infusion - excipient ingredients: egg lecithin; water for injections; sodium hydroxide; glycerol - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake. intralipid 30% is particularly suitable for patients on fluid restriction due to its more concentrated form. this also provides an advantage in patients with a high energy requirement. a lower phospholipid/triglyceride ratio provides less phospholipids than the same amount of energy from intralipid 200mg/l. about 60% of the fatty acids in intralipid are essential fatty acids.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 300 g/l - injection, intravenous infusion - excipient ingredients: glycerol; egg lecithin; sodium hydroxide; water for injections - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake. intralipid 30% is particularly suitable for patients on fluid restriction due to its more concentrated form. this also provides an advantage in patients with a high energy requirement. a lower phospholipid/triglyceride ratio provides less phospholipids than the same amount of energy from intralipid 200mg/l. about 60% of the fatty acids in intralipid are essential fatty acids.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 200 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; egg lecithin; glycerol; water for injections - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 200 g/l - injection, intravenous infusion - excipient ingredients: glycerol; sodium hydroxide; water for injections; egg lecithin - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - soya oil, quantity: 100 g/l - injection, intravenous infusion - excipient ingredients: water for injections; glycerol; egg lecithin; sodium hydroxide - indications: part of the intravenous diet in all parenteral nutrition indications including:- 1. preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; 2. nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); 3. burns, to reduce the frequently-excessive nitrogen losses; 4. prolonged unconsciousness, eg. following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; 5.impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; 6. cachexia; 7. patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

octapharma - amino acids, electrolytes - solution for infusion

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

octapharma - amino acids, electrolytes, glucose - infusion

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

octapharma - amino acids, electrolytes, glucose - infusion